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doi:10.1Objective: Owing to the improved long-term outcome after cardiac transplantation, cardiac allograft vasculop-
athy or valvular disease is developing late after heart transplantation in a growing number of patients. In this
study, we evaluated our results of nonretransplant cardiac surgery in these patients and compared them with those
after retransplantation.
Methods: Since 1983, a total of 867 heart transplantations have been performed at our institution. Among them,
44 patients underwent nonretransplant cardiac surgery, 4 of them repeatedly. The procedures included 19 coro-
nary artery revascularizations, 20 tricuspid valve procedures, 4 other valvular procedures, 4 aortic operations, and
1 right atrial thrombectomy. Long-term results of these patients were compared with those of 20 patients after late
cardiac retransplantation.
Results: Indications for nonretransplant surgery included cardiac allograft vasculopathy, tricuspid regurgitation,
aortic and mitral valve insufficiency, as well as acute aortic dissection type A. Mean interval between heart trans-
plantation and reoperation was 8.4 years. Mean follow-up was 5.8 years. Early mortality was 4.5% (2/44). The
early deaths were caused by intracerebral bleeding and acute rejection. Actuarial survivals at 1, 5, and 7 years
were 84%, 64%, and 58%, respectively. In comparison, early mortality in the retransplant group was 20%
(4/20) and survivals at the same time points were 70%, 70%, and 47%, respectively.
Conclusions: According to these results, we consider nonretransplant surgical options for cardiac allograft vas-
culopathy and valvular disease a safe and effective therapeutic approach with low early mortality and acceptable
long-term results. (J Thorac Cardiovasc Surg 2010;140:433-9)T
XHeart transplantation (HTX) has become an established
treatment option for end-stage heart failure and has been suc-
cessfully performed for more than 30 years. Owing to the
improvement of surgical techniques and immunosuppres-
sive therapy, long-term survival has significantly improved
during this time.1 Thus, an increasing number of patients
have late morbidity after HTX, for example, cardiac allograft
vasculopathy (CAV) and valvular disease.
To date, a limited number of reports, on small patient
populations, have been published in the literature on the
management of posttransplant cardiac disease.
Despite the growing knowledge regarding the pathogenesis
of CAV, treatment options are still limited.2 Coronary angio-
plasty and coronary artery bypass grafting (CABG) are avail-
able therapeutic strategies.3-7 In tricuspid regurgitation (TR),
which is the most common valvular heart disease after
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The Journal of Thoracic and Cathese treatment options are not applicable for all patients,
especially those with severely impaired graft function. Thus,
cardiac retransplantation remains the only definitive therapy
for cardiac allograft failure of any etiology. Unfortunately,
this therapeutic approach is limited by the scarcity of
suitable donor organs and the associated short- and long-
term mortality.15-17 To evaluate the available treatment
options for long-term cardiac morbidity after HTX, we retro-
spectively analyzed our results after nonretransplant cardiac
surgery in patients after HTX.
PATIENTS AND METHODS
Patients
Between July 1983 and December 2008, a total of 867 HTXs have been
performed in 819 patients at our institution. Among them, 44 patients under-
went nonretransplant cardiac operations late after HTX (>30 days), 4 of
which were repeated (Figure 1). The procedures included 19 coronary artery
revascularizations, 20 tricuspid valve procedures, 4 other valvular proce-
dures, 4 aortic operations, and 1 right atrial thrombectomy. Five patients
received cardiac retransplantation late after cardiac reoperation. During
the same period of time, 20 patients underwent cardiac retransplantation
late after HTX. Patients who underwent retransplantation for acute graft
failure, as well as patients with acute cardiac reoperation after HTX, were
excluded from this study. Patient characteristics are summarized in Table 1.
Preoperative Management
Patients coming for surgical reintervention after HTX were thoroughly
evaluated. Less-invasive interventional therapeutic options, such as percu-
taneous coronary angioplasty, were always considered before surgery wasrdiovascular Surgery c Volume 140, Number 2 433
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAV ¼ cardiac allograft vasculopathy
HTX ¼ heart transplantation
MIDCAB ¼ minimally invasive direct coronary
artery bypass grafting
OPCAB ¼ off-pump coronary artery bypass
grafting
TR ¼ tricuspid regurgitation
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Xperformed. All patients received preoperative computed tomographic scans
to define the distance between the heart and sternum. Calcineurin inhibitors
were discontinued at the time of admission for reduction of nephrotoxicity.
Immunosuppression and Follow-up
Immunosuppression consisted of a triple maintenance therapy based on
cyclosporine or tacrolimus, in combination with azathioprine or, more re-
cently, mycophenolate mofetil and steroids. All patients receive steroids
for life. All patients were followed up at our outpatient clinic. Myocardial
biopsy specimens were routinely obtained during the first year or, more re-
cently, during the first 6 months. Routine catheterization was performed
during the first year after transplantation and, depending on the coronary sta-
tus, every second or third year thereafter.
Statistical Methods
Data were prospectively recorded and retrospectively analyzed. Contin-
uous variables were presented as mean  standard deviation and compared
with the independent sample t test. Categorical variables were presented as
proportions and compared by c2 analysis. Actuarial survival was estimated
with the Kaplan-Meier method and analyzed by the log-rank test. All data
were analyzed with the Statistical Program of Social Sciences (SPSS, ver-
sion 16.0; SPSS, Inc, Chicago, Ill).
RESULTS
Patient Population
A total of 48 cardiac reoperations after HTX were
performed in 44 patients. Four patients underwent repeated
(2) surgical procedures. Five patients received a second
HTX late after cardiac reoperation (1-4 years postoperatively)
(Figure 1). Mean age was 51.5  12.5 years (range, 20-70
years). Thirty-three (75%) patients were male and 11 (25%)
female. Mean interval between transplantation and reopera-
tion was 8.4 5.0 years (range, 32 days-21 years). Mean du-
ration of surgery was 223  68 minutes (Table 1). Mean
follow-up was 5.8  4.7 years (range, 19 days-17 years)
with a cumulative follow-up of 256 patient-years.
For comparison, patient characteristics of the 20 patients
who underwent late cardiac retransplantation are presented
in Table 1.
Underlying Diagnoses and Surgical Procedures
Indications for surgery included coronary artery disease,
valvular disease, as well as acute aortic dissection type A.
Surgical procedures are listed in Table 1.434 The Journal of Thoracic and Cardiovascular SurgCABG. Seventeen patients were operated on for coronary
artery disease, among them 14 patients with CAV and 4 pa-
tients with pre-existing coronary artery disease of the graft.
These patients underwent a total of 19 coronary artery revas-
cularizations, either as complete arterial revascularization
(14 procedures) or with a combination of arterial and venous
grafts (5 procedures). Six operations were performed off-
pump, among them 2 minimally invasive direct coronary ar-
tery bypass grafting (MIDCAB) procedures and 4 off-pump
coronary artery bypass grafting (OPCAB) procedures. All
17 patients received a left internal thoracic artery bypass
graft. The right thoracic artery was chosen twice and the ra-
dial artery was used in 9 patients, in 7 of them as a T graft and
in 2 as a free graft. One procedure was an emergency proce-
dure after acute myocardial infarction and 1 was performed
as an urgent procedure 2 weeks after myocardial infarction.
Mean interval between HTX and CABG operation was
9.0 5.5 years. Two patients received repeated coronary re-
vascularizations at 1 week and 1 year after the first operation,
respectively. Two patients underwent late retransplantation
at 1 and 4 years, postoperatively.
Tricuspid valve surgery. Nineteen patients had severe TR.
Four of them received tricuspid valve repair and 15 were
treated with biological tricuspid valve replacement, 1 of
them repeatedly (4 years after the first replacement because
of structural valve deterioration). In 2 patients, an additional
CABG operation was performed because of concomitant
coronary artery disease. Two patients underwent late re-
transplantation at 17 and 20 months, postoperatively. The
mean interval between HTX and tricuspid valve surgery
was 8.6  4.2 years.
Valvular procedures. Four patients had different valvular
pathologic conditions. Among them, 1 patient had aortic,
mitral, and tricuspid valve endocarditis. This patient re-
ceived combined aortic, mitral, and tricuspid valve replace-
ment. Another patient had aortic valve insufficiency 5 years
after valve-sparing aortic root replacement, which was ini-
tially performed for acute aortic dissection type A (see be-
low). The patient underwent aortic valve replacement.
(This patient received a second HTX 2 years later and is still
alive). The third patient underwent mitral valve replacement
for isolated mitral valve insufficiency. The remaining patient
underwent combined mitral and tricuspid valve repair for se-
vere regurgitation. The mean interval between HTX and
valve surgery was 12.3  7.2 years.
Aortic surgery. Three patients had acute aortic dissection
type A at 1 month, 3 years, and 9 years after transplantation.
In all 3 patients, the dissection was limited to the donor part
of the aorta. Valve-sparing aortic root replacement, as de-
scribed by David and Feindel,18 has been performed in
2 cases, whereas in 1 case, the aortic root had to be replaced
because of significant aortic valve regurgitation. Two pa-
tients received an additional venous bypass graft to the rightery c August 2010
FIGURE 1. Cumulative survival after late cardiac reoperation and retrans-
plantation after HTX. Re-OP, Reoperation; Re-HTX, retransplantation.
Goerler et al Cardiothoracic Transplantationcoronary artery because of dissection of the right coronary
ostium. One patient had severe aortic valve regurgitation 5
years after the David operation and underwent aortic valve
replacement (see above). The same patient received cardiac
retransplantation another 2 years later for CAV. One patient
with Marfan syndrome had chronic dissection of the aortic
arch and descending aorta owing to acute aortic dissection
type A before HTX. This patient underwent aortic arch re-
placement. Mean interval between HTX and aortic surgery
was 4.2  3.8 years.
Others. One patient underwent right atrial thrombectomy
3 years after transplant. This patient is currently alive at
year 18 after transplantation.T
XSurvival
Early mortality (30 days) was 4.5% (2/44) in the nonre-
transplant group. Twenty patients died late (>30 days) after
surgery. The 2 early deaths were caused by intracerebral
bleeding in 1 patient, after triple valve replacement for acute
endocarditis, and by acute rejection in the other patient after
tricuspid valve repair. In the CABG group, 9 patients died
late after repeated surgery. Ten patients died late after tricus-
pid valve replacement and 1 died late after combined tricus-
pid and mitral valve repair. All patients receiving surgery for
aortic dissection are still living. Two of the 5 patients who
underwent cardiac retransplantation after nontransplant sur-
gery died late after retransplantation.
Causes of late deaths were acute rejection, chronic graft
failure (CAV and biventricular heart failure), apoplexy, ma-
lignancies (lymphoma and leukemia), and others, including
mesenterial infarction, cardiac arrhythmias resulting from
electrolyte imbalance, septic cerebral embolism, and sudden
deaths of unknown origin. Overall causes of deaths are listed
in Table 1. Actuarial survivals at 1, 3, 5, and 7 years were
84%, 72%, 64%, and 58%, respectively. In comparison,The Journal of Thoracic and Caearly mortality in the retransplant group was 20.0% (4/20)
and survivals at the same time points were 70%, 70%,
70%, and 47%, respectively (Figure 2).
Risk Factor Analysis
For the identification of risk factors for mortality, patient
characteristics, as well as procedure-associated data, have
been used in both univariate and multivariate analyses
(Table 1). However, none of the included variables was
identified as a risk factor for mortality.
DISCUSSION
This study summarizes our experience with cardiac reop-
eration of patients late after HTX. To our knowledge, this is
the largest cohort of patients in literature. As described
above, long-term survival after HTX has significantly im-
proved.1 As a consequence, an increasing number of patients
have recurrent cardiac disease late after HTX. At the same
time, the number of available donor organs is constantly
decreasing. Therefore, the indication for a retransplantation
has to be carefully evaluated and alternative therapeutic
approaches investigated.15,16
According to our results, nonretransplant cardiac surgery
can be performed with low perioperative mortality. There
were 2 early deaths in our patient cohort. One patient had en-
docarditis and received a triple valve replacement—an oper-
ation that is associated with a high operative risk per se. The
other died early after tricuspid valve repair, which was per-
formed 2 months after the original transplantation owing to
severe TR, indicating a pre-existing organ dysfunction. The
favorable short- and long-term outcomes support the deci-
sion for organ-sparing cardiac surgery as the first-line thera-
peutic approach in patients with recurrent cardiac disease
late after HTX.
However, the indications for cardiac retransplantation and
organ-sparing surgery are different and cardiac reoperation is
not an option for all patients, especially those with severely
impaired graft function. Therefore, careful selection of the
therapeutic approach is required for each individual patient.
According to our experience the following aspects have to
be considered for favorable short-and long-term outcomes
after performing cardiac surgery in HTX recipients.
Management of Surgical and Patient-Associated
Risks
Cardiac surgery in patients after HTX is associated with
a combination of specific risks. Among them are an increased
risk of intraoperative and postoperative bleeding owing to
(more or less severe) adhesions after previous surgical proce-
dures, as well as an increased risk of renal failure, infection,
and wound healing disorders owing to long-term immuno-
suppression. To minimize the risk of resternotomy, we per-
formed a computed tomographic scan in every patient
before the operation. The decision for the cannulation siterdiovascular Surgery c Volume 140, Number 2 435
TABLE 1. Patient characteristics
Reoperation
after HTX Retransplantation
P
value
Patients (n) 44 20
Procedures (n) 48 21
Mean age at the time
of surgery (y)
51.5  12.5
(range 20–70)
50.5  10.4
(21–67)
NS
Gender
Male 33 (75%) 18 (90%) NS
Female 11 (25%) 2 (10%)
Interval between HTX and
reoperation/re-TX (y)
8.4  5.0
(0.1–21.0)
7.0  5.2
(0.2–17.1)
NS
Surgical procedures 48 21
CABG 19
Arterial grafts 14
Arterial and venous
grafts
5
TV surgery 20
TV repair 4
TVR 14
TVRþCABG 2
Other valvular procedures 4
AVR 1
MVR 1
AVRþMVRþTVR 1
MVþTV repair 1
Aortic surgery 4
Acute aortic diss.
type A
3
Chronic aortic diss.
type A
1
Other 1
Right atrial
thrombectomy
1
Re-HTX (5*) 20
Re-re-HTX 1
Operation time (min) 223  68
(65–398)
250  97
(145–540)
NS
Thirty-day mortality 2 (4.5%) 4 (20.0%) .049
Overall mortality 22 (50%) 11 (55%) NS
Causes of death
Acute rejection 2 (4.5%) 3 (15.0%)
Initial graft failure 0 2 (10.0%)
Chronic graft failure 2 (4.5%) 1 (5.0%)
Infection 0 1 (5.0%)
Liver failure 0 2 (10.0%)
Cerebral 2 (4.5%) 1 (5.0%)
Malignancy 3 (6.8%) 0
Other 6 (13.6%) 1 (5.0%)
Unknown 7 (15.9%) 0
HTX, Heart transplantation; TX, transplantation; CABG, coronary artery bypass graft-
ing; TV, tricuspid valve; TVR, tricuspid valve replacement; AVR, aortic valve replace-
ment; MVR, mitral valve replacement; MV, mitral valve; NS, not significant. *Not
included in retransplant calculations.
FIGURE 2. Cardiac surgery after HTX: Number of patients who under-
went cardiac reoperations and retransplantations late (>30 days) after pri-
mary heart transplantation between July 1983 and December 2008. HTX,
Heart transplantation; Re-OP, reoperation; Re-HTX, retransplantation.
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Xwas based on the distance between the heart and sternum. In
our study group, femoral cannulation was chosen only once in
a patient with acute aortic dissection type A. Alternatively,436 The Journal of Thoracic and Cardiovascular Surga lateral approach might be favorable, either as a MIDCAB
procedure from the left side or as right-sided thoracotomy
for tricuspid or mitral valve surgery. Among our patients,
this approach has been successfully applied in 4 patients, 2
withMIDCAB procedures and 2 with tricuspid valve replace-
ment. Owing to the impaired renal function of the majority of
patients late after HTX, calcineurin inhibitors were discontin-
ued in all patients at the time of admission. Postoperatively,
oral immunosuppression was preferred to intravenous appli-
cation whenever possible. If technically feasible, off-pump
procedures were chosen. When cardiopulmonary bypass
was required, pulsatile pump flow was preferred.19
CABG Surgery
In the majority of our study population, listed in Table 2,
coronary artery disease was diagnosed by routine catheteri-
zation inasmuch as typical symptoms, such as angina, were
often missing. Two patients had amyocardial infarction, em-
phasizing the importance of routine catheterization after
HTX. The first catheterization after HTX is especially im-
portant to identify the coronary status of the allograft. In
our study group, 4 patients had relevant coronary artery ste-
nosis of the graft, which was successfully treated by CABG
operation. To date, 3 of them are still alive. With respect to
surgical technique, we prefer arterial bypass grafts in these
patients because of the favorable long-term patency rates
and technical advantages in MIDCAB and OPCAB proce-
dures (the aorta is not touched).20 Another reason for the
choice of arterial grafts was the lack of sufficient vein graft
material after previous CABG operations (3 patients).
Thus far, only few reports have been published about cor-
onary artery revascularization after HTX, summarized in
Table 3. Musci and associates5 reported on 7 patients with
CABG surgery after HTX; among them, 4 required emer-
gency procedures. They concluded that it depended on theery c August 2010
TABLE 2. CABG surgery after HTX
No.
Previous
interventions
Catheter
indication Lesion type EF No. of grafts AV
Surgical
access Reintervention Reoperation
Survival
(d)
1 None Routine C/LMCA (CAD of
the graft)
Normal LITA (1) OPCAB None None 196
2 None Angina/
infarction
B/C Slightly reduced LITA (1), VG (2) Standard None None 2928
3 None Routine B/C Slightly reduced LITA (1), RA (2) Standard None None 967
4 2 3 PCI Routine A/C/LMCA Severely reduced LITA (1), RA (1) Standard None Re-TX 2975
5 None Routine C (CAD of the
graft)
Normal LITA (2) OPCAB None None 2669
6 1 3 PCI Limited physical
activity
B/C Medium reduced LITA (1), RA (1) Standard None None 100
7 None Routine A (CAD of the
graft)
Normal LITA (1), RA (1)
(þTEA)
Standard 1 3 PCI None 3305
8 1 3 PCI Routine A/B Normal LITA (1), VG (1) OPCAB None None 3184
9 None Routine B/C Slightly reduced LITA (1), VG (2) Standard 2 3 PCI None 4343
10 2 3 PCI Routine C/LMCA Normal LITA (1) MIDCAB 3 3 PCI RITA (1), RA (1) 2933
11 None Routine B/C/LMCA (CAD
of the graft)
Normal LITA (1), RITA
(1), RA (1)
Standard None None 3423
12 None Routine B/C Normal LITA (1), RA (1) Standard None None 3271
13 1 3 PCI Routine B Normal LITA (1) OPCAB None None 719
14 2 3 PCI Routine B Medium reduced LITA (1), RA (2) Standard None None 295
15 6 3 PCI Routine B/C/LMCA Severely reduced LITA (1), RA (1) Standard None RITA (1) 1140
16 1 3 PCI Routine C Slightly reduced LITA (1) MIDCAB 1 3 PCI Re-TX 2741
17 None Routine A/C/LMCA Normal LITA (1), VG (3) Standard None None 919
CABG, Coronary artery bypass grafting; HTX, heart transplantation; EF, ejection fraction; AV, arterial/venous; LMCA, left main coronary artery; CAD, coronary artery disease;
LITA, left internal thoracic artery; OPCAB, off-pump coronary artery bypass grafting; VG, vein graft; RA, radial artery; PCI, percutaneous coronary intervention; Re-TX, retrans-
plantation; TEA, thromboendarterectomy; MIDCAB, minimally invasive direct coronary artery bypass grafting; RITA, right internal thoracic artery; A, B and C, type A, B and C
lesions.
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Xmorphologic characteristics of coronary lesions whether a pa-
tient could be successfully treated or not (type A lesions vs
type B and C lesions). According to our experience, patients
with CAV often have diffuse coronary artery sclerosis with
a history of multiple stent implantations. These patients can
be successfully treated by surgical revascularization (espe-
cially in case of additional left main stem stenosis) so long
as suitable localizations for bypass grafts can be identified.
Halle and coworkers3 presented outcome data of 12 patients
after posttransplant CABG surgery. They remarked that
owing to the low number of patients, the assessment of this
procedure was still limited. Additionally, the mean follow-
up of both studies was relatively short at 9 and 10 months,
respectively. The largest number of patients after surgical re-
vascularization after HTX has been published by Bhama and
colleagues.7 They reported on 13 patients with amean follow-
up of 39 months. They concluded that CABG operation after
HTX is a viable treatment optionwith goodmedium-term out-
comes. Owing to the key role of CAV as the major cause of
death after HTX and the major cause for retransplantation,1,2
further studies that provide long-term follow-up data of this
patient population are urgently required for further evaluation
of the different treatment options.
Another aspect of CABG surgery in HTX recipients is the
increasing shortageof suitable donor organs, leading to the ex-The Journal of Thoracic and Catension of donor criteria. In this situation, there is the tendency
toward accepting donor organs with known or suspected cor-
onary artery disease.21,22 A simultaneous CABG procedure
can be performed in these patients; however, long-term results
of this approach are lacking. Among our patients, 4 acciden-
tally received an allograft with pre-existing coronary artery
disease, as described above. Theyunderwent successful surgi-
cal revascularization, indicating that the aforementioned
extension of donor criteria might, in fact, be justified.
Valve Surgery
TR is the most common valvular disease after HTX.8
Owing to structural defects of the tricuspid valve, repair
has been performed in only 4 of 19 patients in our study
group. As we9 have shown before, tricuspid valve replace-
ment seems to be superior to reconstruction after HTX.
There are several reports on treatment options in TR after
HTX that are summarized in Table 4. Filsoufi and associ-
ates13 report on 8 patients who had tricuspid valve surgery
after HTX. Six of them were primarily treated with tricuspid
valve repair. However, in 3 of them repair failed and second-
ary valve replacement was necessary. Alharethi and
coworkers12 share our preference for tricuspid valve replace-
ment versus tricuspid valve repair in this patient group
because of the underlying structural leaflet defects.rdiovascular Surgery c Volume 140, Number 2 437
TABLE 3. Literature review: CABG surgery after HTX*
Patients/ procedures (n)
Interval between HTX and
surgery, mo (range) Kind of surgery (n) Deaths early/late (n)
Follow-up,
mo (range)
Halle 19953 12/12 57  20 10 CABG
1 CABGþAVR
1 CABGþTVR
4/1 9  7
Patel 19974 6/6 54  13 (24–89) 5 CABG
1 CABGþTMLR
3/2 23y (2–64)y
Musci 19995 7/7 67 (6–128) 6 CABG
1 CABGþTVR
3/0 10 (2–32)
Rothenburger 20056 7/7 58 (26–114) 7 CABG 0/2 ?
Bhama 20097 13/14 147  75 (15–251) 14 CABG 0/3 39  36 (0.3–110)
Goerler 17/19 108  65 (1–212) 19 CABGz 0/11 69  44 (3–142)
CABG, Coronary artery bypass grafting; HTX, heart transplantation; AVR, aortic valve replacement; TVR, tricuspid valve replacement; TMLR, transmyocardial laser revascular-
ization. *Included were only studies with more than 5 patients. yCalculated from available data. zTwo patients after CABGþTVR are not included.
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XWong and coworkers8 summarize their review about the
treatment of TR after HTX as follows: tricuspid valve repair
should be considered in cases of dilated tricuspid annulus;
however, a bioprosthetic valve replacement is preferred in
leaflet prolapse and biopsy-induced chordal injury. How-
ever, the actual aim must be the prevention of TR, which
is ultimately achieved by the appropriate implantation tech-
nique. All but 1 patient who required tricuspid valve surgery
after HTX at our institution underwent transplantation be-
fore 2000. Until then, orthotopic HTX was performed by
the technique described by Lower and Shumway.23 Cur-
rently, the bicaval implantation technique is used in all pa-
tients, except for small children. As the Cleveland group
has shown, the bicaval implantation technique was associ-
ated not only with a significantly reduced incidence of TR,
and thereby significantly better preserved cardiac function,
but also with a significantly improved survival after trans-TABLE 4. Literature review: Tricuspid valve surgery after HTX*
Patients/procedures
(n)
Interval between HTX
and surgery, mo (range) Ki
Wahlers 19969 12/12 70  32y 8
Yankah 200010 17/18 105 (2–161)
(þ2 C
Chan 200111 6/6 ?
Alharethi 200612 17/18 77  48
Filsoufi 200613 8/11 21x (2–84)
Musci 200714 19/19 78 (2–180)
Goerler 19/20 103  50 (2–200)
HTX, Heart transplantation; TVR, tricuspid valve replacement; TV, tricuspid valve; CABG, c
yCalculated from available data. zSurvivors. xOnly first surgical procedure. kOne patient a
438 The Journal of Thoracic and Cardiovascular Surgplantation.24 Another preventive strategy in the context of
TR is the reduction in endomyocardial biopsies. Several
studies have reported an association between the frequency
of endomyocardial biopsies and TR.8 Therefore, and owing
to the improvement of echocardiography, the number of rou-
tine myocardial biopsies has been significantly reduced at
our institution. Preventive strategies also include tricuspid
valve annuloplasty during HTX as described by the Philade-
phia group.25 They found a perioperative mortality advan-
tage in the group with prophylactic DeVega tricuspid
valve annuloplasty. Long-term cardiac mortality was re-
duced in that group as well. On the basis of their results,
they recommend tricuspid valve annuloplasty as a routine
adjunct to orthotopic HTX. However, although significant
TR develops in a significant number of patients late after
HTX, as we26 have reported previously, surgery is required
in only a small minority of symptomatic patients.8,10,25nd of surgery (n) Deaths early/late (n)
Follow-up,
mo (range)
TVR 4 TV repair
(þ1 CABG)
0/2 ? (3–21)z
11 TVR
7 TV repair
ABG;þ8 other proc.)
1/5 30 (4–81)
6 TVR 0/0 13  7 (6–24)
16 TVR
2 TV repair
1/1 33  50 (0–154)
5 TVR
6 TV repair
2 55 (TVR) 72 (TV repair)
12 TVR
7 TV repair
(þ3 CABG)
3/4 35 (0–97)
16 TVRk
4 TV repair
(þ2 CABG)
1/10 77  66 (1–200)
oronary artery bypass grafting. *Included were only studies with more than 5 patients.
fter aortic valve replacement and mitral valve replacement is not included.
ery c August 2010
Goerler et al Cardiothoracic TransplantationAcute Aortic Dissection Type A
In our study population, acute aortic dissection type A oc-
curred in 3 patients at different times after transplantation. In
all patients, the dissection was limited to the donor part of the
aorta below the suture line, which prevented further exten-
sion of the dissection. A common risk profile of these pa-
tients was not identified. Obviously, the limitation of the
dissection to the donor part of the aorta is not mandatory.
Rothenburger and colleagues6 presented the cases of
2 patients with acute aortic dissection requiring combined
ascending aorta and aortic arch replacement; one of them
survived the procedure. Both dissections occurred during
the fifth year after transplantation. Another patient with
type B dissection underwent endovascular stent implanta-
tion. Knosalla and associates27 summarized their experience
with HTX in 10 patients with Marfan syndrome. Among
them, 2 patients underwent replacement of the thoracoabdo-
minal aorta for chronic dissection, 14 and 20 months after
transplantation, and both patients survived. Another patient
died 4 years after HTX owing to ruptured aortic dissection
type B. In summary, acute aortic dissection can be success-
fully treated in HTX recipients.Limitations of the Study
Although this is a large cohort of patients with a long
follow-up as compared with other studies reported in litera-
ture, the overall number of patients remains low. To this
point, differences between the 2 groups might be missed,
as well as risk factors for mortality. Owing to the retrospec-
tive character of the study, echocardiographic assessment of
ventricular function was incomplete, especially in patients of
the early era. Therefore, ejection fraction has not been in-
cluded in the analysis of risk factors.T
XCONCLUSION
According to these results, we consider nonretransplant
surgical options for CAV and valvular disease a safe and
effective therapeutic approach with acceptable long-term re-
sults. Although the definitive treatment option for all kinds
of cardiac allograft failure remains cardiac retransplantation,
nonretransplant surgical options have to be considered as
first-line therapy whenever possible, owing to the scarcity
of suitable donor organs and associated short-termmortality.References
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